BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/18/2017 1:45:25 AM | Browse: 632 | Download: 485
Publication Name World Journal of Hepatology
Manuscript ID 32603
Country/Territory Singapore
2017-01-17 10:07
Peer-Review Started
2017-01-18 13:54
To Make the First Decision
2017-05-08 09:23
Return for Revision
2017-05-09 16:29
2017-05-20 00:55
Second Decision
2017-06-02 00:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-06-13 05:03
Articles in Press
2017-06-13 05:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-08-14 08:00
Publish the Manuscript Online
2017-08-18 01:45
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Use of everolimus in liver transplantation
Manuscript Source Invited Manuscript
All Author List Mei-Ling Yee and Hui-Hui Tan
Funding Agency and Grant Number
Corresponding Author Mei-Ling Yee, Senior Principal Clinical Pharmacist, Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. yee.mei.ling@sgh.com.sg
Key Words Everolimus; Mammalian target of rapamycin inhibitor; Immunosuppression; Liver transplantation; Nephrotoxicity
Core Tip Everolimus is the most recently approved im­munosuppressant for use in liver transplantation (LT). Its renoprotective effect is an attractive option for LT recipients who have calcineurin inhibitor-induced nephrotoxicity. This review examines through data published, discovers gaps of evidences and discusses the place in therapy for everolimus (EVR) in LT. At the end of review, it summarises how EVR can benefit LT recipients as well as the caveat in using EVR.
Publish Date 2017-08-18 01:45
Citation Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol 2017; 9(23): 990-1000
URL http://www.wjgnet.com/1948-5182/full/v9/i23/990.htm
DOI http://dx.doi.org/10.4254/wjh.v9.i23.990
Full Article (PDF) WJH-9-990.pdf
Full Article (Word) WJH-9-990.doc
Manuscript File 32603-Review.docx
Answering Reviewers 32603-Answering reviewers.pdf
Audio Core Tip 32603-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 32603-Conflict-of-interest statement.pdf
Copyright License Agreement 32603-Copyright assignment.pdf
Peer-review Report 32603-Peer-review(s).pdf
Scientific Misconduct Check 32603-Scientific misconduct check.pdf
Scientific Editor Work List 32603-Scientific editor work list.pdf